Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population

NCT: NCT06790355 · COMPLETED

NCT IDNCT06790355
StatusCOMPLETED
Start Date2025-03-01
Completion2026-08-31
SponsorShanghai Weihe Medical Laboratory Co., Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.

Frequently Asked Questions

What is ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population?

ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population is a clinical trial registered under NCT06790355. Current status: COMPLETED.

What is the status of NCT06790355?

The current status of NCT06790355 (ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population) is: COMPLETED.

When did ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population start?

ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population started on 2025-03-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑